xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 2021, 3, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22741 by Stanford University, Wiley Online Library on [01/07/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

442

International consensus statement on rhinosinusitis

antibiotics, with rotation to avoid drug resistance. Dalm 1281 2012 5 Expert opinion Thymosin1 α may have an effect on

Ryan 1294 2010 5 Expert opinion Recommended prophylactic antibiotics, early, aggressive, culture-directed

antibiotic treatment; and possible use IVIG.

Ryan 1298 2008 5 Expert opinion Advocated prompt treatment with culture-directed antibiotics and the use of IVIG.

Treatment was of little benefit in patients with R-CRS with an underlying immunodeficiency.

Kuruvilla 1296 2013 5 Commentary/ review Approximately half of the therapeutic dose is proposed for prophylactic

Study Year LOE Study Design Study Groups Clinical Endpoint Conclusions Stevens 1288 2015 4 Literature review Diagnosis of antibody deficiency in patients with CRS is important because of the large clinical implications it can have on sinus disease management. Buehring 1297 1997 4 Prospective case series (open trial) MRI Nasal lavage for ECP, IL-8, TNF- α Nasal culture

Ocampo 1293 2013 5 Expert opinion Recommended prophylactic antibiotics, Ig replacement if indicated, and early ESS.

monocyte function, a possible new target for therapy in R-CRS.

Fergusson 1295 2009 5 Expert opinion Culture-directed antibiotics should be administered more promptly than in patients with normal immunity.

16 R-CRS treated with azithromycin, N-acetylcysteine, and topical intranasal beclomethasone

TABLE IX-44 (Continued)